CD36 deficiency rescues lipotoxic cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Metabolic Diseases
• Molecular Cardiology

Background:

• Obesity and diabetes mellitus cause increased myocardial fatty acid (FA) uptake, leading to lipotoxic cardiomyopathy.
• Chronic activation of peroxisome proliferator-activated receptor alpha (PPARalpha) drives diabetic heart dysfunction.
• Cardiac-restricted PPARalpha overexpression in mice (MHC-PPARalpha) results in lipid accumulation and cardiac dysfunction.

Purpose of the Study:

• To investigate the role of the long-chain FA transporter CD36 in the pathophysiology of lipotoxic cardiomyopathy.
• To determine if CD36 deficiency can prevent or ameliorate cardiac dysfunction in a model of PPARalpha-induced lipotoxicity.

Main Methods:

• Mice with cardiac-specific PPARalpha overexpression (MHC-PPARalpha) were crossed with CD36-deficient mice (MHC-PPARalpha/CD36-/-).
• Cardiac function, myocyte lipid accumulation, and gene expression related to FA and glucose metabolism were assessed under basal and high-fat diet conditions.

Main Results:

• Absence of CD36 prevented myocyte triacylglycerol accumulation and cardiac dysfunction in MHC-PPARalpha mice.
• CD36 deficiency led to increased cardiac glucose uptake and oxidation, not altered FA utilization.
• PPARalpha-mediated suppression of glucose metabolism genes was reversed in CD36-deficient mice, while FA oxidation gene expression remained unchanged.

Conclusions:

• CD36 is a necessary mediator for the development of lipotoxic cardiomyopathy in this model.
• Targeting CD36-mediated FA uptake presents a potential therapeutic strategy for obesity- and diabetes-related cardiac dysfunction.